[1] Lin C H, Chen M L, Tai Y C, et al. Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population[J]. Am J Med Genet B Neuropsychiatr Genet, 2013, Sep 3..[2] Mizuta I, Takafuji K, Ando Y, et al. YY1 binds to alpha-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression[J]. J Hum Genet, 2013, Sep 12..[3] Brockmann K, Schulte C, Hauser A K, et al. SNCA: Major genetic modifier of age at onset of Parkinson's disease[J]. Mov Disord, 2013, 28(9):1217-1221.[4] Chang C, Lang H, Geng N, et al. Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD[J]. Neurosci Lett, 2013, 548:190-195.[5] Shaltiel-Karyo R, Frenkel-Pinter M, Rockenstein E, et al. A blood-brain barrier(BBB) disrupter is also a potent alpha-synuclein(alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease(PD)[J]. J Biol Chem, 2013, 288(24):17579-17588.[6] Peng X, Tehranian R, Dietrich P, et al. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells[J]. J Cell Sci, 2005, 118(Pt15):3523-3530.[7] Wu J, Lou H, Alerte T N, et al. Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo[J]. Neuroscience, 2012, 207:288-297.[8] Yang W, Wang X, Duan C, et al. Alpha-synuclein overexpression increases phospho-protein phosphatase 2A levels via formation of calmodulin/Src complex[J]. Neurochem Int, 2013, 63(3):180-194.[9] 程芙蓉, 李昕, 殷娟娟, 等.过氧化氢和帕金森病患者血清促进α-突触核蛋白向线粒体与细胞核转运[J].首都医科大学学报, 2010, 31(6):732-736.[10] Yu S, Zuo X, Li Y, et al. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells[J]. Neurosci Lett, 2004, 367(1):34-39.[11] Czapski G A, Gassowska M, Wilkaniec A, et al. Extracellular alpha-synuclein induces calpain-dependent overactivation of cyclin-dependent kinase 5 in vitro[J]. FEBS Lett, 2013, 587(18):3135-3141. |